Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

Company Overview - Tourmaline Bio, Inc. is a late-stage clinical biotechnology company focused on developing transformative medicines for patients with immune and inflammatory diseases [3] - The company's lead asset is pacibekitug, a long-acting, fully-human, anti-IL-6 monoclonal antibody with potential best-in-class properties [4] Upcoming Event - Tourmaline will host a conference call and webcast on May 20, 2025, at 8:30 a.m. ET to present topline results from the Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease [1] - Dr. Deepak L. Bhatt, a prominent figure in cardiovascular medicine, will join the management team during the presentation [1] Product Details - Pacibekitug has a naturally long half-life, low immunogenicity, and high binding affinity to IL-6, making it a promising candidate for various indications [4] - The drug has been previously studied in approximately 450 participants across six completed clinical trials, focusing on autoimmune disorders [4] - Tourmaline is currently developing pacibekitug for atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED), with plans to expand into abdominal aortic aneurysm (AAA) and other diseases in the future [4]